Sarepta Therapeutics 주식 (NASDAQ: SRPT)

에 대한 최신 뉴스 Sarepta Therapeutics (NASDAQ:SRPT) 주식

SAREPTA THERAPEUTICS INC

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Nvidia, AMD, Archer Aviation, Rocket Lab, And Tesla: Why Are These 5 Stocks On Investors' Radars Today

Equities

News

Markets

NVDA

QBTS

SRPT

TSLA

화요일(18일) 미국 증시는 투자자들이 연준의 금리 결정을 기다리면서 하락했다. 화요일 주목받은 주식: 엔비디아, 메타, 사렙타, D-웨이브 및 테슬라

화요일 주목받은 주식: 엔비디아, 메타, 사렙타, D-웨이브 및 테슬라

The Archer Aviation Trade

Mid Cap

Movers

Trading Ideas

ACHR

ARWR

BHVN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IREN

JOBY

SOUN

SRRK

URBN

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아처 에비에이션(NYSE:ACHR) 주식은 지난주 65.57% 급등했다.

아처 및 어번 아웃피터스는 지난주 최고 성과를 보여준 8개 중형주 중 일부 (11월 25일-29일)

rivian shutter2

Large Cap

CPRT

ESTC

EXAS

MRNA

RIVN

RKLB

SNAP

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $40 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Sarepta Therapeutics, Maintains $40 Price Target

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SRPT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Sarepta Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 44% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $26,890, and 8 calls, totaling $413,005.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $60.0 for Sarepta Therapeutics during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Sarepta Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Sarepta Therapeutics's whale trades within a strike price range from $25.0 to $60.0 in the last 30 days. 
<h3>Sarepta Therapeutics Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747839657_0_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.6</td>
<td>$8.3</td>
<td>$9.6</td>
<td>$35.00</td>
<td>$96.0K</td>
<td>1.1K</td>
<td align="right">10</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$9.3</td>
<td>$6.6</td>
<td>$7.6</td>
<td>$35.00</td>
<td>$76.0K</td>
<td>118</td>
<td align="right">100</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.35</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$55.00</td>
<td>$63.2K</td>
<td>21</td>
<td align="right">305</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.1</td>
<td>$0.95</td>
<td>$0.99</td>
<td>$55.00</td>
<td>$53.7K</td>
<td>1.2K</td>
<td align="right">564</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.8</td>
<td>$3.6</td>
<td>$3.8</td>
<td>$55.00</td>
<td>$38.0K</td>
<td>483</td>
<td align="right">265</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
In light of the recent options history for Sarepta Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Sarepta Therapeutics Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,260,400, the SRPT's price is up by 2.8%, now at $41.11. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About Sarepta Therapeutics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $109.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Sarepta Therapeutics, targeting a price of $100. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Sarepta Therapeutics, targeting a price of $113. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Sarepta Therapeutics, targeting a price of $84. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Sarepta Therapeutics, targeting a price of $125. 
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Sarepta Therapeutics with a target price of $123. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Sarepta Therapeutics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On Sarepta Therapeutics

WIIM

Sarepta Therapeutics shares are trading higher after the company provided dosing updates on its ENVISION study of ELEVIDYS.

Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy.
We have received feedback from the Medicines &amp; Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. ENVISION is a global, randomized, double-blind, placebo-controlled Phase 3 study of ELEVIDYS in non-ambulatory and older ambulatory individuals with Duchenne.
About ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle.
In the U.S., ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age.
<ul>
<li>For patients who are ambulatory and have a confirmed mutation in the DMD gene</li>
<li>For patients who are non-ambulatory and have a confirmed mutation in the DMD gene.</li>
</ul>
The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Biotech

General

Sarepta Provides Update On UK Dosing in ENVISION Study Of ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy. Company Received Feedback From The Medicines And Healthcare Products Regulatory Agency In U.K That Dosing May Continue Uninterrupted In Envision, Study Srp-9001-303

Analysts' ratings for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) over the last quarter vary from bullish to bearish, as provided by 30 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">12</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $109.8, a high estimate of $202.00, and a low estimate of $40.00. Highlighting a 20.62% decrease, the current average has fallen from the previous average price target of $138.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1747749667_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Sarepta Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$58.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$98.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$87.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$99.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$161.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Sell</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Sarepta Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>Delving into Sarepta Therapeutics's Background</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
<h3>Understanding the Numbers: Sarepta Therapeutics's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sarepta Therapeutics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 80.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -60.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -33.52%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -12.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 1.18. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $169 to $84.

JP Morgan Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $84

- Treatment with ELEVIDYS for Duchenne muscular dystrophy resulted in mean protein expression of 93.87% as measured by western blot in study participants (n=6)
- Safety profile consistent with prior studies of ELEVIDYS and real-world experience

Sarepta Therapeutics Shares Safety Results From ENDEAVOR Study In 2-Year-Old Participants

<ul>
<li>Significant functional benefits for 8- and 9-year-olds with Duchenne in Part 2 of the EMBARK study, contributing to the evidence of stabilization or slowing of disease progression in later childhood when muscle weakness typically progresses</li>
<li>Statistically significant differences were observed on all key endpoints including 4.75 points (P=0.0026) on North Star Ambulatory Assessment (NSAA), 6.87 seconds in time-to-rise (TTR) from the floor (P=0.0010), and 4.76 seconds in 10-meter walk/run (10MWR) (P=0.0097) compared to a well-matched external control cohort
<ul>
<li>Five abstracts, including two oral presentations at American Society of Gene &amp; Cell Therapy Conference, span Sarepta's portfolio of approved and pipeline therapies across Duchenne and limb-girdle muscular dystrophy</li>
</ul>
</li>
</ul>

Events

Sarepta Therapeutics Presents Part 2 EMBARK Data At American Society of Gene & Cell Therapy Conference

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">early-stage breast cancer</a>.
After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) treatment, compared with individuals who received Herceptin, chemotherapy, and placebo.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" target="_blank" rel="noreferrer noopener">Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs</a>
After ten years, <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-05-13" rel="noreferrer noopener">results</a> show:
<ul class="wp-block-list">
<li>91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, p-value=0.044).</li>
<li>A 21% reduction in the risk of death was seen in the prespecified subgroup of people with lymph node-positive disease (HR=0.79).</li>
<li>The previously reported invasive disease-free survival (primary endpoint) benefit was maintained (HR=0.79), strengthening results from earlier APHINITY analyses. No benefit was seen in the node-negative subgroup.</li>
<li>The safety profile, including cardiac safety, was consistent with previous studies, and no new or unexpected safety signals were identified.</li>
</ul>
Full results will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.
In April, Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) and&nbsp;Roche temporarily&nbsp;halted&nbsp;several clinical studies for Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
The company reported a patient death following treatment with Elevidys, having suffered&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
In April, Roche&#8217;s MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous infusion for relapsing multiple sclerosis did not meet its primary endpoint in showing additional benefit in slowing disability progression compared with the currently approved <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613949/why-is-pharma-giant-roche-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Ocrevus IV 600 mg dose</a>.
Price Action: RHHBY stock is trading at $38.34 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45383468/earnings-just-put-dan-loebs-bets-to-the-testheres-what-held-up" target="_blank" rel="noreferrer noopener">Earnings Just Put Dan Loeb&#8217;s Bets To The Test — Here&#8217;s What Held Up</a></li>
</ul>
Photo by OleksSH via Shutterstock

Health Care

RHHBY

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

Legal

Japanese Ministry Of Health, Labour, And Welfare Approved Sarepta Theraperutics' ELEVIDYS For Treatment Of Duchenne Muscular Dystrophy Under Conditional And Time-Limited Approval Pathway In Japan

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets experienced a notable upswing this week, driven by President Donald Trump's announcement of a trade agreement with the United Kingdom. The deal includes reductions in tariffs on UK automobiles, steel, and aluminum, and grants the UK access to the U.S. beef market. This development spurred optimism for potential future trade agreements and contributed to a rally in equities, with the S&amp;P 500 and Nasdaq posting gains. Additionally, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surpassed the $100,000 mark, reflecting increased investor confidence and a shift toward riskier assets.
Despite the positive market response, concerns about the broader economic outlook persist. The Federal Reserve opted to maintain current interest rates, citing uncertainties related to the new tariff policies and their potential impact on inflation and employment. Analysts warn of the risk of stagflation — a combination of stagnant economic growth and high inflation—especially as the effects of the tariffs become more pronounced.
Looking ahead, high-level trade discussions between U.S. and Chinese officials are scheduled, aiming to address ongoing tensions and possibly adjust existing tariffs. Investors are closely monitoring these developments, as outcomes could significantly influence market dynamics and economic forecasts in the coming months.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/25/05/45259042/ibm-thinks-big-ai-delivers-bigger-why-bulls-are-charging-toward-300">"IBM Thinks Big, AI Delivers Bigger – Why Bulls Are Charging Toward $300"</a>, by Surbhi Jain, reports that International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) shares have climbed 48% over the past year and 13% year-to-date, driven by strong technical indicators and a bullish AI strategy, prompting Wedbush analyst Dan Ives to reiterate an Outperform rating with a $300 price target.
<a href="https://www.benzinga.com/25/05/45295534/novavax-reports-q1-profit-as-revenue-surges-to-over-600-million-and-lower-costs-raises-2025-forecasts">"Novavax reports Q1 profit as revenue surges to over $600 million and lower costs, raises 2025 forecasts"</a>, by Vandana Singh, reports that Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) posted a Q1 profit of $2.93 per share on $667 million in revenue — driven by $603 million from terminated advance purchase agreements — while raising its 2025 revenue forecast to $975 million-$1.025 billion and noting ongoing discussions with the FDA for full approval of its COVID-19 vaccine.
<a href="https://www.benzinga.com/25/05/45297555/hims-hers-stocks-100-surge-is-squeezing-shorts-and-it-might-just-be-getting-started">"Hims &amp; Hers stock's 100% surge is squeezing shorts—and it might just be getting started"</a>, by Surbhi Jain, reports that Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares have doubled over the past month, fueled by strong Q1 earnings, a partnership with Novo Nordisk to offer Wegovy, and a high short interest of 33% of float, suggesting a classic short squeeze may be underway.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">Chipmakers Enter Bullish Seasonal Window: 5 Stocks That Could Outperform</a>
<a href="https://www.benzinga.com/25/05/45291509/nvidia-broadcom-amd-surge-as-trump-reshapes-ai-chip-export-rules-to-ease-market-pressure">Nvidia, Broadcom, AMD Gain As Trump Reshapes AI Chip Export Rules To Ease Market Pressure</a>
<a href="https://www.benzinga.com/news/earnings/25/05/45268589/sunrun-stock-rallies-after-strong-q1-report-details">Sunrun Stock Rallies After Strong Q1 Report: Details</a>

The Bears
<a href="https://www.benzinga.com/news/earnings/25/05/45268429/arm-holdings-stock-plunges-after-q4-results-heres-why">"Arm Holdings Stock Plunges After Q4 Results: Here's Why"</a>, by Erica Kollmann, reports that Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares fell nearly 9% after the company beat Q4 expectations with $1.24 billion in revenue and $0.55 EPS but issued weaker-than-expected guidance for fiscal 2026, citing uncertainty in licensing deals and global trade tensions.
<a href="https://www.benzinga.com/25/05/45272331/super-micro-slides-as-ai-server-delays-nvidia-supply-limits-weigh-on-analyst-ratings">"Super Micro slides as AI server delays, Nvidia supply limits weigh on analyst ratings"</a>, by Anusuya Lahiri, reports that Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares fell 5% after the company missed Q3 revenue and EPS expectations and issued a cautious Q4 outlook, attributing delays to customers awaiting NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell GPUs and facing supply constraints, leading analysts to lower forecasts amid concerns over AI server demand and margin pressures.
<a href="https://www.benzinga.com/25/05/45261806/sarepta-therapeutics-stock-sinks-on-gloomy-forecast-analysts-cut-price-forecasts">"Sarepta Therapeutics stock sinks on gloomy forecast, analysts cut price forecasts"</a>, by Vandana Singh, reports that Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares fell after the company posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/news/earnings/25/05/45239188/arista-networks-shares-fall-after-mixed-q1-results-eps-beat-revenues-miss-q2-guidance-below-estimates">Arista Networks Shares Fall After Mixed Q1 Results: EPS Beat, Revenues Miss, Q2 Guidance Below Estimates</a>
<a href="https://www.benzinga.com/news/earnings/25/05/45270996/cleveland-cliffs-stock-falls-on-q1-earnings-miss-steelmaker-idles-6-facilities-taking-decisive-action-to-streamline-our-operations">Cleveland-Cliffs Stock Falls On Q1 Earnings Miss, Steelmaker Idles 6 Facilities: ‘Taking Decisive Action To Streamline Our Operations'</a>
<a href="https://www.benzinga.com/news/earnings/25/05/45302422/coinbase-q1-earnings-highlights-revenue-eps-miss-2025">Coinbase Slips On Q1 Miss, Highlights SEC ‘Win' And Strategic Bitcoin Reserve Executive Order</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

$BTC

AMAT

ANET

AVGO

COIN

MRVL

MSFT

NVAX

ORCL

SMCI

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets

Regulations

Opinion

CAPR

New FDA Leadership Could Raise The Bar For Drug Approvals

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Prothena Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, Prothena posted weaker-than-expected quarterly results. &#8220;We continue to meaningfully advance our wholly-owned and partnered programs across our protein dysregulation portfolio during this transformative year for Prothena. Most notably in 2025 we anticipate topline data in 2Q from the confirmatory Phase 3 AFFIRM-AL clinical trial evaluating birtamimab for AL amyloidosis, conducted under a SPA agreement with the FDA with a primary endpoint of time to all-cause mortality at a statistical significance level of 0.10,&#8221; said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. The company's stock fell around 31% over the past month and has a 52-week low of $7.01.</li>
<li>RSI Value: 21.9</li>
<li>PRTA Price Action: Shares of Prothena fell 2.6% to close at $7.10 on Thursday.</li>
<li>Edge Stock Ratings: 5.29 Momentum score with Value at 79.24. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PRTA"><img loading="lazy" decoding="async" width="486" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png" alt="" class="wp-image-909704" style="width:347px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png 486w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96-300x104.png 300w" sizes="(max-width: 486px) 100vw, 486px" /></a></figure>
<h3 class="wp-block-heading">Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 7, RxSight posted mixed quarterly results. &#8220;The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons,&#8221; said Ron Kurtz, Chief Executive Officer and President of RxSight. The company's stock fell around 15% over the past month and <a href="https://www.benzinga.com/quote/RXST">has a 52-week low</a> of $13.22.</li>
<li>RSI Value: 28.8</li>
<li>RXST Price Action: Shares of Rxsight dipped 11.2% to close at $13.23 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">RXST stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="917" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png" alt="" class="wp-image-909712" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-768x693.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. "In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion," said Doug Ingram, CEO of Sarepta Therapeutics. The company's stock fell around 42% over the past five days and has a 52-week l<a href="https://www.benzinga.com/quote/SRPT">ow of $35.4</a>6.</li>
<li>RSI Value: 23.2</li>
<li>SRPT Price Action: Shares of Sarepta Therapeutics fell 0.5% to close at $36.52 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">SRPT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="876" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png" alt="" class="wp-image-909714" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-768x730.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

PRTA

RXST

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $115 to $100.

Wells Fargo Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $100

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sector Perform and lowers the price target from $87 to $58.

RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $58

Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) reported on Tuesday that the first-quarter 2025 loss of&nbsp;$3.42 per share was missing the analyst consensus estimate of&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">losses of 95 cents</a>.
Quarterly revenue came in at $744.86 million,&nbsp;beating the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45235113/sarepta-therapeutics-announces-first-quarter-2025-financial-results-and-recent-corporate-developme" rel="noreferrer noopener">estimate of&nbsp;$683.36 million</a>.
According to Sarepta CEO Doug Ingram, the company also <a href="https://www.benzinga.com/general/biotech/25/05/45254051/vinay-prasads-appointment-to-fdas-cber-triggers-questions-over-future-of-cell-and-gene-therapy-re" target="_blank" rel="noreferrer noopener">faced headwinds in the quarter</a>. 
&#8220;While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,&#8221; Ingram said. &#8220;The broader biotech market has also faced significant pressure in the first quarter of 2025. Fortunately, as an organization with four life-changing therapies, significant revenue, and a deep pipeline, Sarepta is well-positioned to navigate these chaotic times.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death</a>
Guidance: Sarepta revised its 2025 total net product revenues guidance to $2.3-$2.6 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42954480/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-revenue" rel="noreferrer noopener">from $2.9-$3.1 billion</a>.
William Blair writes that the revised guidance primarily relates to delayed Elevidys turnaround times.
The time from starting treatment paperwork to actual infusion takes about 1 to 1.5 months longer than expected. This delay is mostly due to stricter screening steps added to protect patients in the larger treatment group, analyst Sami Corwin says. Although the company is trying to speed things up and reduce delays, it expects these early-year trends to continue throughout the rest of the year.
&#8220;We view the miss in total net product and Elevidys revenue as unfortunate and disappointing given the macroeconomic overhangs that have already caused the stock to come under pressure,&#8221; William Blair writes.
The analyst adds that management believes the impact on Elevidys's revenue will be temporary, and expects demand to pick up in the second half of the year, starting in the summer.
<ul>
<li>William Blair maintains <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Guggenheim maintains Sarepta with a Buy, lowering the price target from $112 to $98.</li>
<li>Piper Sandler keeps the Overweight rating for Sarepta, lowering the price target from $110 to $70.</li>
<li>Oppenheimer maintains Sarepta with an Outperform, lowering the price target from $184 to $123.</li>
<li>Cantor Fitzgerald reaffirms the company&#8217;s Overweight rating and lowers the price target from $163 to $81.</li>
<li>HC Wainwright maintains Sarepta with a Neutral, lowering the price target from $75 to $40.</li>
<li>Morgan Stanley maintains Sarepta with an Overweight, lowering the price target from $182 to $113.</li>
<li>Needham maintains Sarepta with a Buy and lowers the price target from $183 to $125.</li>
</ul>
Price Action: Sarepta Therapeutics stock is down 19.4% at $37.67 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45258853/geo-missed-q1-targets-on-rising-costs-and-debt-guides-q2-below-street-estimates" target="_blank" rel="noreferrer noopener">GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

Goldman Sachs analyst Salveen Richter maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and lowers the price target from $178 to $100.

Goldman Sachs Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $100

Guggenheim analyst Debjit Chattopadhyay maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and lowers the price target from $112 to $98.

Guggenheim Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $98

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $110 to $70.

Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $70

Oppenheimer analyst Hartaj Singh maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $184 to $123.

Oppenheimer Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $123

Press Releases

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Alvotech

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Metsera

Nuvalent

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

JP Morgan

Wells Fargo

RBC Capital

Goldman Sachs

화요일(18일) 미국 증시는 투자자들이 <a href="https://in.benzinga.com/government/regulations/25/03/44364688/feds-march-meeting-expected-to-signal-no-hurry-on-rate-cuts-as-powell-likely-to-tread-carefully" target="_blank" rel="noopener">연준의 금리 결정</a>을 기다리면서 하락했다. 다우존스 산업평균지수는 0.6% 하락한 41,581.31포인트에 마감했고, S&amp;P 500 지수는 거의 1.1% 하락한 5,614.66포인트에 거래를 마쳤다. 나스닥은 1.7% 하락하여 17,504.12포인트에 마감했다.
화요일에 소매 투자자와 트레이더의 주목을 받은 주요 주식은 다음과 같다.
<h3>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</h3>
화요일 엔비디아 주가는 3.43% 하락하여 115.43달러에 마감했다. 주가는 장중에 119.02달러로 최고가를 기록했으며, 최저가는 114.54달러였다. 52주 주가 범위는 75.61~153.13달러다. 엔비디아 CEO인 젠슨 황은 엔비디아의 블랙웰 기반 AI 기술을 자율주행 및 제조에 통합하기 위해 <a href="https://www.benzinga.com/tech/25/03/44383445/nvidia-ceo-jensen-huang-announces-gm-partnership-the-time-for-autonomous-vehicles-has-arrived" target="_blank" rel="noopener">GM과 파트너십</a>을 맺었다고 발표했다. 또한 GTC 2025에서 황은 "피지컬 AI"의 부상과 다양한 산업에서 엔비디아의 역할이 커지고 있음을 강조했다.
<h3>메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</h3>
메타의 주가는 3.73% 하락하여 582.36달러로 마감했으며, 장중 최고가는 600.25달러, 최저가는 574.66달러였다. 주가의 52주 최고가와 최저가는 각각 740.89달러 및 414.5달러다. 울프 리서치의 애널리스트들은 메타가 현재 시장에서 저평가된 <a href="https://in.benzinga.com/markets/25/03/44374847/meta-could-rake-in-30-40-billion-in-revenue-from-whatsapp-business-messaging-predicts-analyst" target="_blank" rel="noopener">비즈니스 메시징 서비스</a>에서 300억~400억 달러의 매출을 올릴 수 있을 것으로 예상하고 있다.
<h3>사렙타 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)</h3>
사렙타의 주가는 27.44% 급락해 최고가 81.87달러, 최저가 73.06달러로 마감하며 52주 신저가를 기록했다. 이러한 하락은 듀센 근이영양증에 대해 유일하게 승인된 치료법인 <a href="https://in.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" target="_blank" rel="noopener">엘리비디스(Elevidys) 유전자 치료제</a>로 치료 후 환자가 사망했다는 회사의 보고 이후 나왔다.
<h3>D-웨이브 퀀텀 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)</h3>
D-웨이브 퀀텀 주가는 3.40% 하락하여 10.80달러로 마감했으며, 최고가는 11.50달러, 최저가는 9.48달러였다. 52주 범위는 0.75~11.50달러다. GPU 기술 컨퍼런스의 일환인 엔비디아의 퀀텀 데이를 앞두고 <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44385434/d-wave-quantum-shares-traded-lower-tuesday-what-happened" target="_blank" rel="noopener">양자 주식</a>이 변동성에 직면하면서 하락세를 보였다.
<h3>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</h3>
테슬라의 주가는 5.34% 하락하여 225.31달러로 마감했으며, 장중 최고가 230.10달러, 최저가 222.28달러를 기록했다. 52주 범위는 138.80~488.54달러다. 그러나 일론 머스크가 이끄는 테슬라의 주가는 시간외 거래에서 거의 1.1 % 상승했다. 정규 거래의 하락은 엔비디아와 제너럴 모터스가 자율주행 차량에 대한 파트너십을 발표하면서 테슬라의 시장 지위에 영향을 미쳤기 때문에 발생했다.
<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이 8개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아처 에비에이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) 주식은 지난주 65.57% 급등했다.
2. 스칼러 락 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) 주식은 경쟁사인 바이오헤이븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)의 척수성 근위축증에 대한 탈데프그로베프(taldefgrobep)가 <a href="https://www.benzinga.com//node/42169246" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3상 연구에 실패한 후</a> 주가는 49.61% 급등했다.
3. 애로우헤드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) 주식은 사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)와 여러 임상 및 전임상 siRNA 프로그램에 대한 글로벌 라이선스 및 협력 계약을 체결한 후 42.40% 상승했다.
4. 아이리스 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) 주식은 회사가 1분기 실적을 발표하고 여러 애널리스트가 주가 전망을 상향 조정한 후 38.99% 급등했다.
5. 힘스 앤 허스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 주식은 대통령 당선인 도널드 트럼프가 마티 마카리(Marty Makary)를 식품의약국(FDA) 수장으로 지명할 계획을 발표한 후 33.42% 상승했다.
6. 사운드하운드 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) 주식은 33.38% 상승했다. 이 회사는 최근 <a href="https://www.benzinga.com//node/42145826" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">AEMA 그룹의 일부로 아피비아 쿠르타주</a>(Apivia Courtage)에 대화형 AI 에이전트인 아멜리아(Amelia)를 배포했다고 발표했다.
7. 조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) 주식은 토요타 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>)가 이 회사에 5억 달러를 투자했다는 발표 후 31.62% 상승했다.
8. 어번 아웃피터스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) 주식은 회사가 3분기 실적을 발표하고 여러 애널리스트가 주가 전망을 상향 조정한 후 30.43% 상승했다.
 
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A6%AC%EB%B9%84%EC%95%88-%EB%A1%9C%EC%BC%93%EB%9E%A9-%EB%B0%8F-%EB%AA%A8%EB%8D%94%EB%82%98%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC/" target="_blank" rel="noopener">리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7-%EA%B7%B8%EB%9E%A9-%EB%B0%8F-%EC%98%A4%ED%86%A0%EB%8D%B0%EC%8A%A4%ED%81%AC-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-11/" target="_blank" rel="noopener">레딧, 그랩 및 오토데스크 지난주 최악의 성과를 보인 11개 대형주 중 일부 (11월 25일-29일)</a></li>
</ul>
이미지 출처: Archer


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 리비안 오토모티브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>)의 주식이 22.06% 급등했다. 이는 회사가 <a href="https://www.benzinga.com//node/42184005" target="_blank" rel="noreferrer noopener">66억 달러의 에너지부(DOE)의 대출 약정</a>을 확보한 후 발생한 일이다.
2. 로켓랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/42216210" target="_blank" rel="noreferrer noopener">뉴멕시코 주에서 반도체 운영을 강화하기 위한 2,390만 달러의 칩스(CHIPS) 법안 지원금</a>을 확보한 후 21.73% 상승했다.
3. 사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주식이 20.67% 상승했다. 이는 회사가 애로우헤드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>)와 <a href="https://www.benzinga.com//node/42196870" target="_blank" rel="noreferrer noopener">여러 임상 및 비임상 siRNA 프로그램</a>에 대한 글로벌 라이선스 및 협력 계약을 발표한 후 발생한 일이다.
4. 이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)의 주식이 16.98% 상승했다. 이는 메디케어 및 메디케이드 서비스 센터가 <a href="https://www.benzinga.com//node/42195803" target="_blank" rel="noreferrer noopener">2025년 임상 실험실 수수료 일정</a>에 대한 최종 지급 결정을 발표한 후 발생한 일이다.
5. 엘라스틱 N.V.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>)의 주식이 16.29% 상승했다. 웨드부시 증권의 애널리스트인 댄 아이브스가 인공지능(AI) 혁명의 다음 단계에 대한 낙관론을 크게 높인 후 발생한 일이다. 그는 소프트웨어 분야에 대한 <a href="https://www.benzinga.com//node/42171519" target="_blank" rel="noreferrer noopener">변혁적 영향을 강조</a>했다.
6. 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식이 14.13% 상승했다. 이는 씨티그룹의 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/ulta/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정</a>한 후 발생한 일이다.
7. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식이 지난 주 12.58% 급등했다.
8. 랄프 로렌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)의 주식이 지난 주 11.72% 상승했다.
9. 코파트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>)의 주식은 회사가 예상보다 좋은 1분기 매출 실적을 발표한 후 11.41% 상승했다.
10. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식이 12.18% 상승했다. 이는 씨티그룹의 애널리스트들이 주식의 <a href="https://www.benzinga.com/quote/snap/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 전망을 상향 조정</a>한 후 발생한 일이다.
 
사진 출처: rblfmr via Shutterstock


다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>맥케슨 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)의 주가는 예상보다 나쁜 FY25 <a href="https://www.benzinga.com//node/40232820" target="_blank" rel="noreferrer noopener">1분기 매출 실적</a>을 보고한 후 12.06% 하락했다. 분석가들은 회사의 <a href="https://www.benzinga.com/quote/mck/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 수정했다.</li>
<li>바이오-테크네(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>)는 예상보다 나쁜 4분기 매출 결과로 지난주 주가가 11.71% 하락했다.</li>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주가는 부진한 <a href="https://www.benzinga.com//node/40234107" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>에 따라 10.62% 하락했다. 몇몇 분석가들은 주식에 대한 등급과 <a href="https://www.benzinga.com//node/40264035" target="_blank" rel="noreferrer noopener">목표 주가</a>를 업데이트했다.</li>
<li>찰스 리버 래보래토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)의 주가는 2분기 실적에서 10.41% 하락했고 FY24 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener">조정된</a> 전망도 하향 조정됐다. 애널리스트들은 해당 주식의 <a href="https://www.benzinga.com/quote/crl/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>를 낮췄다.</li>
<li>사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주가는 예상보다 부진한 2분기 매출로 인해 9.33% 하락했다. 회사는 추정치보다 낮은 FY25 순 제품 매출 지침을 발표했으며 몇몇 분석가들은 주식에 대한 <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">가격 예측을 하향 조정</a>했다.</li>
<li>몬스터 베버리지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>)가 <a href="https://www.benzinga.com//node/40233200" target="_blank" rel="noreferrer noopener">2분기 재무 결과</a>를 발표한 후 주가가 8.95% 급락했다. 많은 분석가들이 <a href="https://www.benzinga.com/quote/mnst/analyst-ratings" target="_blank" rel="noreferrer noopener">목표</a> 가격을 하향 조정했다.</li>
<li>탑빌드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주가는 예상보다 나쁜 <a href="https://www.benzinga.com//node/40182863" target="_blank" rel="noreferrer noopener">분기 실적 결과</a>에 따라 8.93% 하락했다. 몇몇 분석가들은 회사의 <a href="https://www.benzinga.com/quote/bld/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 가격</a>을 낮췄다.</li>
<li>에어비앤비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)의 주가는 회사가 예상보다 나쁜 분기별 EPS 실적을 보고하고 예상치보다 낮은 <a href="https://www.benzinga.com//node/40203008" target="_blank" rel="noreferrer noopener"> 3분기 매출 전망</a>을 발표한 후 7.01% 하락했다. 많은 분석가들은 <a href="https://www.benzinga.com//node/40227192" target="_blank" rel="noreferrer noopener">목표</a> 가격을 낮췄다.</li>
<li>어드밴스드 드레이니지 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>)의 주가는 <a href="https://www.benzinga.com//node/40246477" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 실적 부진</a>으로 인해 6.94% 하락했다.</li>
<li>SBA 커뮤니케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>)의 주식은 지난주 6.85% 떨어졌다.</li>
</ol>
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%eb%b0%8f-%ed%8c%94%eb%9e%80%ed%8b%b0%ec%96%b4%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10/" target="_blank" rel="noopener">쇼피파이 및 팔란티어는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 4일-8월 10일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABNB

DELL

MNST

SBAC

TECH

워너 브라더스 및 맥케슨은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 4일-8월 10일)

이들 대형주들은 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주가는 회사가 엘리비디스(ELEVIDYS)의 라벨 표시 적응증에 최소 4세 이상의 듀센 <span class="c5aZPb" tabindex="0" role="button" data-enable-toggle-animation="true" data-extra-container-classes="ZLo7Eb" data-hover-hide-delay="1000" data-hover-open-delay="500" data-send-open-event="true" data-theme="0" data-width="250" data-ved="2ahUKEwijqpmq3vKGAxXva_UHHc50CRoQmpgGegQIERAD">근이영양증(DMD) 유전자 돌연변이가 확인된 듀센 근이영양증 환자를 포함하도록 확장하는 것에 대한 미 식품의약국(FDA)의 승인을 발표한 후 29.50% 상승했다. 또한, 여러 투자 은행들이 해당 종목에 대해 <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 목표 주가를 상향 조정</a>했다.</li>
<li>시리우스 XM 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)의 주가는 지난주 16.73% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)의 주가는 지난주 15.57% 상승했다.</li>
<li>길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 주가는 <a href="https://www.benzinga.com//node/39435732" target="_blank" rel="noreferrer noopener">긍정적인 3단계 HIV 데이터</a> 이후 지속적인 강세를 보이며 지난주 12.62% 상승했다.</li>
<li>츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주가는 10.59% 상승했다. 이는 5월 <a href="https://www.benzinga.com//node/39385252" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">o온라인 매장에서의 소매 구매가 증가</a>한 후 주가가 올랐을 가능성이 크다.</li>
<li>액센츄어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>)의 회사가 3분기 실적을 <a href="https://www.benzinga.com//node/39410240" target="_blank" rel="noreferrer noopener">발표한 이후</a> 주가는 9.80% 상승했다. 몇몇 분석가들은 가격 예측을 <a href="https://www.benzinga.com/quote/acn/analyst-ratings" target="_blank" rel="noreferrer noopener">하향 조정</a>했습니다.</li>
<li>드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)의 주가는 지난주 9.69% 상승했다. 이는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39316935/draftkings-stock-can-overcome-wall-of-worry-around-various-regulatory-risks-analyst">6월 30일까지 최종 확정되어야 할 뉴저지 2025년 예산안에 세금을 도입하지 않을 것으로 예상되어, 플로리다의 온라인 스포츠 베팅의 미래에 중대한 영향을 미칠 결정에 따른 주가 상승으로 보입니다.</a></li>
<li>이러한 급증은 플로리다 온라인 스포츠 베팅의 미래에 중요한 영향을 미치는 미국 대법원의 중추적 결정과 6월 30일까지 확정되어야 하는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39316935/draftkings-stock-can-overcome-wall-of-worry-around-various-regulatory-risks-analyst">뉴저지의 2025년 예산에 세금</a>이 도입되지 않을 것이라는 낙관론에 따른 것이다.</li>
<li>델(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)의 주가는 일론 머스크가 회사의 xAI가 구축하고 있는 슈퍼컴퓨터에 들어갈 이 랙의 절반을 조립하고 있다고 <a href="http://dell%20shares%20are%20trading%20higher%20after%20elon%20musk%20said%20the%20company%20is%20assembling%20half%20of%20the%20racks%20that%20are%20going%20into%20the%20supercomputer%20that%20xai%20is%20building./" target="_blank" rel="noopener">말한</a> 후 지난주 8.19% 상승했다.</li>
<li>오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)의 주가는 스타보드(Starboard)가 이 회사의 지분을 5억 달러 보유하고 있다고 <a href="https://www.benzinga.com//node/39357211">보도된 이후</a> 7.99% 상승했다.</li>
<li>골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주가는 7.15% 상승했다. <a href="https://www.benzinga.com//node/39416585" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">금값 상승 속</a>에 금 광산주 주가가 상승세를 보이고 있다.</li>
</ol>
사진제공: 셔터스톡
다음 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

ADSK

CELH

CHWY

DKNG

GILD

SIRI

TOST

드래프트킹스와 델은 지난주 최고의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)

목요일 아침(현지 시간 기준) 미국 주식 선물이 더 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li><a href="https://pro.benzinga.com/dashboard">벤징가 프로</a>의 데이터에 따르면 월스트리트에서는 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)이 시장 마감 후 분기별 이익을 주당 1.50달러, 매출 900억 1천만 달러로 보고할 것으로 예상된다. 애플 주가는 시간외 거래에서 1.09% 상승한 171.14달러에 거래되었다.</li>
<li>아르셀로미탈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>)은 1분기에 예상 이상의 실적을 발표하였다. 수요일 아셀로미탈은 tlrksdhl rjfodptj 1.72% 상승하여 25.50달러에 도달했다.</li>
<li>분석가들은 코노코필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)가 매출 150.5억달러에 주당 2.04달러의 분기 이익을 발표할 것으로 예상하고 있다. 이 회사는 시장 개장 전에 실적을 발표할 예정이다.</li>
</ul>
여기를 클릭해 <a href="https://www.benzinga.com/premarket/">프리마켓 동향</a>을 확인하세요.
<ul>
<li>사렙타 테라퓨릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)은 수요일 1분기에 대한 낙관적인 결과를 발표했다. 이 회사는 1주당 73센트의 조정된 이익과 4억 1,346.4만 달러의 매출을 기록했다. 사렙타 테라퓨틱스는 시간외 거래에서 5.92% 상승한 138.65달러에 거래되었다.</li>
<li>분석가들은 켈라노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>)가 목요일 시장 개장 전 주당 85센트의 분기 이익과 매출 31.6억달러에 기록할 것으로 예상하고 있다. 켈라노바는 시간외 거래에서 1% 상승한 57.57달러에 거래되었다.</li>
</ul>

Comments

Sarepta Therapeutics

뉴스

에 대한 최신 뉴스 Sarepta Therapeutics (NASDAQ:SRPT) 주식

수요일, 3월 19, 2025

일요일, 12월 01, 2024

일요일, 8월 11, 2024

일요일, 6월 23, 2024

목요일, 5월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌